Sep 2026· Perm Medical Journal· 0 citations· 53 references
TL;DR
Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.
Abstract
The data on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its phenotypes, the evolution of steatotic liver disease terminology and its association with cardiovascular diseases were summarized. A systematic search for relevant publications in the PubMed database was performed.
MASLD has become one of the most prevalent and underappreciated cardiovascular threats. It is closely associated with the development and progression of atherosclerotic cardiovascular diseases, arrhythmias, conduction disorders, hypertension and heart failure. Moreover, MASLD is a crucial part of the cardiohepatorenal continuum. Raising awareness of MASLD among the general public and at-risk populations, unifying existing guidelines for cardiometabolic diseases, and the development of regional and global strategies to combat MASLD are essential to tackle the cardiometabolic pandemic.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associate...
Kyung-Soo Kim, S. Lim, Cheol-Young Park· EXCLI Journal : Experimental...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide. People with MASLD can progress to cirrhosis and have an increased risk of developing hepatic decompensation and hepatocellular carcinoma. People with MASLD are also at increased risk of type 2 diabe...
S. Schuth, K. Kantartzis, A. Birkenfeld et al.· Diabetes & Metabolism Jo...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, and its high prevalence underscores the central role of metabolic dysregulation in its pathogenesis. Recent epidemiological studies have shown that MASLD is associated not only with hepatocellular carcino...
Shi-Yu Peng, Zhui Ke, Han Ding et al.· British journal of hospital...· 0 citations
People with MASLD are at increased risk of developing hepatic decompensation and hepatocellular carcinoma, and are also at increased risk of type 2 diabetes mellitus, cardiovascular disease, and chronic kidney disease.
S. Schuth, K. Kantartzis, A. Birkenfeld et al.· 0 citations
Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...
N. Chew, Chandramouli Chanchal, W. Tay et al.· Open Heart· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.